Abstract
Introduction Trastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary toxicity, patient selection is essential. Currently HER-2/neu analysis is routinely performed only for primary invasive breast cancers, and trastuzumab therapy is recommended based on primary analysis only. Methods Using immunohistochemistry, we performed a retrospective study comparing HER-2/neu expression in original primary to subsequent metastatic breast cancers. Results Tumors from 382 patients with metastatic breast cancer were studied. In 254 cases (66%) both primary and metastatic lesions were concordant. In 90 cases the primary lesion was HER-2/neu positive with the metastatic lesion negative; whereas, in 37 cases the primary lesion was HER-2/neu negative and the metastatic lesion positive. Primary HER-2/neu immunostaining was associated with a negative predictive value of 35.7%. Although all four groups were similar at diagnosis, survival differences were noted with the best survival experienced by patients with initial primary lesions HER-2/neu negative and subsequent metastatic lesions positive. Patients with hormone receptor and HER-2/neu positive primary lesions who received tamoxifen were more likely to have HER-2/neu positive metastasis. Conclusions The significant discordance between HER-2/neu expression in primary and metastatic tumors suggests that determination of HER-2/neu status in metastatic disease should be attempted.
Similar content being viewed by others
References
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
Finn RS, Slamon DJ (2003) Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 21:223–233
Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51
Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M (2007) Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 43:497–509
Niehans GA, Singleton TP, Dykoski D, Kiang DT (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230–1235
Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T et al (2000) c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73:17–20
Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61:5345–5348
Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036–1043
Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P et al (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141–1146
Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552–556
Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S (2005) Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 90:65–70
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235
Heffelfinger SC, Lower EE, Miller MA, Fenoglio-Preiser CM (1996) Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer. A comparative study. Am J Clin Oncol 19:552–557
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739–749
Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC et al (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4(Suppl 3):S1–S22; quiz S23–S24.:S1–S22
Heffelfinger SC, Yassin R, Miller MA, Lower EE (2000) Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies correlation: with vascularity. Pathobiology 68:129–136
Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H (2002) Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15:116–124
Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF (2004) Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918–926
Barrett C, Magee H, O’Toole D, Daly S, Jeffers M (2007) Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 60:690–693
Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101:9393–9398
Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM (2007) A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 25:634–641
Montemurro F, Valabrega G, Aglietta M (2006) Trastuzumab treatment in breast cancer. N Engl J Med 354:2186
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analyses of published randomized trials. BMC Cancer 7:153
Acknowledgements
The authors thank Robert P. Baughman, M.D. and Sue Heffelfinger, M.D., Ph.D. for their expertise and careful review of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lower, E.E., Glass, E., Blau, R. et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113, 301–306 (2009). https://doi.org/10.1007/s10549-008-9931-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-9931-6